BRPI0513423A - derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes - Google Patents

derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes

Info

Publication number
BRPI0513423A
BRPI0513423A BRPI0513423-4A BRPI0513423A BRPI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A
Authority
BR
Brazil
Prior art keywords
alkyl
blood sugar
treatment
aryl
diabetes
Prior art date
Application number
BRPI0513423-4A
Other languages
English (en)
Inventor
Stefan Petry
Karl-Heinz Baringhaus
Norbert Tennagels
Guenter Mueller
Reinhard Kirsch
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0513423A publication Critical patent/BRPI0513423A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE SALICILTIAZOL SUBSTITUìDOS COM DIFENILAMINA E COMPOSTOS RELACIONADOS COMO INIBIDORES DE FOSFATASE DE FOSFOTIROSINA 1B (PTP1B), PARA UTILIZAçãO COM SUBSTáNCIAS ATIVAS REDUTORAS DE AçúCAR NO SANGUE, PARA TRATAMENTO DE DIABETES. A presente invenção refere-se a compostos que desenvolvem um efeito terapêutico para diminuir o açúcar do sangue. Os compostos são particularmente apropriados para prevenção e tratamento de diabetes mellitus. A invenção refere-se, portanto, a compostos da fórmula (I), na qual significam: R1, R2, R3, R4, R5, independentemente um do outro,H, F,CL,Br,I,OH,CF~ 3~, NO~ 2~ ,CN, OCF~ 3~, O-(C~ 1~-C~ 6~)-alquila, O-(C~ 1~-C~ 4~)-alcóxi-(C~ 1~-C~ 4~)-alquila, S-(C~ 1~-C~ 6~)-alquila, (C~ 1~-C~ 6~)-alquila, (C~ 2~-C~ 6~)-alquenila, (C~ 3~-C~ 8~)-cicloalquila, O-(C~ 3~-C~ 8~)-cicloaquila, (C~ 3~-C~ 8~)-cicloalquia, (C~ 3~-C~ 8~)-cicloalquenila, O-(C~ 3~-C~ 8~)-cicloalquenila, (C~ 2~-C~ 6~)-alquinila, arila, O-aril (C~ 1~-C~ 8~)-alquileno-arila, O-(C~ 1-C~ 8~)-alquileno-arila, S-arila, CO-NH(C~ 1~-C~ 6~)-alquila, N(C~ 1~-C~ 6~)-alquil)2, NH-SO~ 2~-CH3, SO~ 2~-CH~ 3~, COOH, COO-(C~ 1~-C~ 6~)-alquila, CO-N((C~ 1~-C~ 6~)-alquil)~ 2~; R6: H, (C~ 1~-C~ 6~)-alquila; A: uma ligação, -CH~ 2~-, -NH-, -CH~ 2~-O-, -S-, -CH~ 2~-CH~ 2~-, -CH(CH~ 3~)-; B: NH, NH(C~ 1~-C~ 4~)-alquila, NH(CO); D: fenila, heterociclo; bem comoos sais fisiologicamente compatíves dos mesmos.
BRPI0513423-4A 2004-07-17 2005-07-02 derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes BRPI0513423A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004034697A DE102004034697A1 (de) 2004-07-17 2004-07-17 Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP2005/007151 WO2006007959A1 (de) 2004-07-17 2005-07-02 Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes

Publications (1)

Publication Number Publication Date
BRPI0513423A true BRPI0513423A (pt) 2008-05-06

Family

ID=34971604

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513423-4A BRPI0513423A (pt) 2004-07-17 2005-07-02 derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes

Country Status (21)

Country Link
US (1) US7741491B2 (pt)
EP (1) EP1771426B1 (pt)
JP (1) JP2008506643A (pt)
KR (1) KR20070043787A (pt)
CN (1) CN100582098C (pt)
AR (1) AR049588A1 (pt)
AT (1) ATE381551T1 (pt)
AU (1) AU2005263418A1 (pt)
BR (1) BRPI0513423A (pt)
CA (1) CA2574162A1 (pt)
DE (2) DE102004034697A1 (pt)
DK (1) DK1771426T3 (pt)
ES (1) ES2296199T3 (pt)
HK (1) HK1104534A1 (pt)
IL (1) IL180570A0 (pt)
MX (1) MXPA06014443A (pt)
PE (1) PE20060554A1 (pt)
PT (1) PT1771426E (pt)
TW (1) TW200616985A (pt)
UY (1) UY29020A1 (pt)
WO (1) WO2006007959A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2003032916A2 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
WO2003048140A1 (fr) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬

Also Published As

Publication number Publication date
ES2296199T3 (es) 2008-04-16
US20070191441A1 (en) 2007-08-16
JP2008506643A (ja) 2008-03-06
CN100582098C (zh) 2010-01-20
PE20060554A1 (es) 2006-06-24
CN1989116A (zh) 2007-06-27
UY29020A1 (es) 2006-02-24
WO2006007959A1 (de) 2006-01-26
HK1104534A1 (en) 2008-01-18
ATE381551T1 (de) 2008-01-15
AR049588A1 (es) 2006-08-16
TW200616985A (en) 2006-06-01
CA2574162A1 (en) 2006-01-26
DE102004034697A1 (de) 2006-02-09
DK1771426T3 (da) 2008-05-05
EP1771426B1 (de) 2007-12-19
KR20070043787A (ko) 2007-04-25
EP1771426A1 (de) 2007-04-11
US7741491B2 (en) 2010-06-22
DE502005002310D1 (de) 2008-01-31
AU2005263418A1 (en) 2006-01-26
IL180570A0 (en) 2007-06-03
PT1771426E (pt) 2008-01-31
MXPA06014443A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
BRPI0513423A (pt) derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
HRP20010468B1 (en) Azabicycloalkanes as ccr5 modulators
UY30013A1 (es) 5-aril isoxazolinas para controlar plagas de invertebrados
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ZA200602077B (en) Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-up-take inhibitors
JO2935B1 (en) 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine)
CR9462A (es) Inhibidores de la dipeptidil peptidasa-iv
EA200800285A1 (ru) Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
AR041299A1 (es) Derivados de pirrolidona como inhibidores de maob
JP2008506643A5 (ja) 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ1b(ptp1b)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
EA200802403A1 (ru) Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, а также содержащие их средства
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
AR064307A1 (es) Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
RU2010128940A (ru) Производные бензилфенилциклогексана и способы их применения
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
WO2008022060A3 (en) Imidazo-pyridine derivatives for modulating protein kinase activity
EA200900478A1 (ru) Жидкая пестицидная композиция, содержащая n-фенилсемикарбазоновые пестицидные соединения
AR072874A1 (es) Compuestos insecticidas
WO2008028805A3 (de) Verwendung einer pharmazeutischen zusammensetzung enthaltend ein anticholinergikum zur abtötung von mikroorganismen und zur behandlung von atemwegsinfektionen
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.